Les traitements en cours de développement dans l’arthrose

Augustin Latourte , Pascal Richette
{"title":"Les traitements en cours de développement dans l’arthrose","authors":"Augustin Latourte ,&nbsp;Pascal Richette","doi":"10.1016/j.monrhu.2021.01.002","DOIUrl":null,"url":null,"abstract":"<div><p>The pharmalogical therapies currently available for the management of osteoarthritis are limited, either because of they have a modest effect-size, or because they can expose elder patients with often multiple comorbidities to a substantial risk of potentially dangerous side effects. The prevalence of osteoarthritis increases consistently, and there is therefore a major need for new treatments to treat the symptoms of osteoarthritis, but also to slow or stop the progression of the disease. The better understanding of the pathophysiology of osteoarthritis has led to the identification of new therapeutic targets, and some drugs related to these targets are currently being studied in phase 2 or 3 randomized controlled trials. These include anti-NGF antibodies, sprifermin, Wnt or cathepsin K inhibitors, some of which have shown promising results. Their long-term tolerance profile remains to be determined. Also, the benefit:risk ratio of anti-NGF antibodies, which induce rapidly progressive arthropathies, remains to be determined. These new treatments could, however, offer new therapeutic prospects for patients in the coming years.</p></div>","PeriodicalId":101125,"journal":{"name":"Revue du Rhumatisme Monographies","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.monrhu.2021.01.002","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue du Rhumatisme Monographies","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1878622721000114","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The pharmalogical therapies currently available for the management of osteoarthritis are limited, either because of they have a modest effect-size, or because they can expose elder patients with often multiple comorbidities to a substantial risk of potentially dangerous side effects. The prevalence of osteoarthritis increases consistently, and there is therefore a major need for new treatments to treat the symptoms of osteoarthritis, but also to slow or stop the progression of the disease. The better understanding of the pathophysiology of osteoarthritis has led to the identification of new therapeutic targets, and some drugs related to these targets are currently being studied in phase 2 or 3 randomized controlled trials. These include anti-NGF antibodies, sprifermin, Wnt or cathepsin K inhibitors, some of which have shown promising results. Their long-term tolerance profile remains to be determined. Also, the benefit:risk ratio of anti-NGF antibodies, which induce rapidly progressive arthropathies, remains to be determined. These new treatments could, however, offer new therapeutic prospects for patients in the coming years.

目前正在开发的骨关节炎治疗方法
目前可用于治疗骨关节炎的药物治疗是有限的,要么是因为它们的效果不大,要么是因为它们可能使患有多种合并症的老年患者面临潜在危险副作用的巨大风险。骨关节炎的患病率持续增加,因此需要新的治疗方法来治疗骨关节炎的症状,同时也要减缓或阻止疾病的进展。对骨关节炎病理生理的更好理解导致了新的治疗靶点的确定,一些与这些靶点相关的药物目前正在进行2期或3期随机对照试验的研究。其中包括抗ngf抗体、spriffermin、Wnt或组织蛋白酶K抑制剂,其中一些已经显示出有希望的结果。它们的长期耐受性仍有待确定。此外,抗ngf抗体诱导快速进展性关节病的获益:风险比仍有待确定。然而,这些新的治疗方法可能在未来几年为患者提供新的治疗前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信